The experience of use of drugs of vegetative origin in the clinic of internal diseases demonstrates their efficiency, in particular for therapy of chronic cardiovascular system diseases. Phytopreparations have some advantages over synthetic ones, as they rare show adverse side effects and are well tolerable by patients. Preparation Cratal, developed by State scientific center of drugs and produced by SPC “Borschagovsky CPP”, is one of new pharmacological preparations for the use in cardiology. Granulated Cratal in 1 g packages and 1 g tablet contain 0.043 g thick Crataеgus oxycante extract, 0.87 g thick Leonurus cardiaca extract and 0.867 g taurine. Both extracts contain mainly flavonoids and their glycosides as well as organic compounds of different chemical structure, however pharmacological action of the majority of them has a topical cardiotropic character. It is just the complex of biologically active substances, contained in the preparation that results in synergism of therapeutic effect of its separate components. Taurine, a non-protein sulfur-containing b-amino-aminoethanesufonic acid, having inotropic action on cardiac muscle and participating in regulation of cardiomycetes metabolism, is an important component of preparation Cratal. Taurine directly participates, first of all, in metabolic processes of carbohydrate and protein exchange and has a membrane-stabilizing effect due to inhibition of lipids peroxidation (LPO). A cardioprotecting effect of Taurine was discovered in experimental study of its action on functional status of cardiovascular system, with ischemic and reperfusive myocardium damage. In doing so, significant anti-arrhythmic and hypotension effects of taurine and its important role in exchange of ions Na+, K+ and Са2+ in cardiomycetes with overload of cardiac muscles, caused by activation of sympatho-adrenal system, was defined. Peculiar chemical properties of Taurine molecule condition its unique action as a universal modulator of the level of cytoplasmatic Ca2+ and of intracellular “calcium agonist”. It was experimentally demonstrated that cardioprotecting properties of Taurine are conditioned by its action on secondary messengers and on hemic hypoxia processes, i.e. that it has a direct antioxidant6 activity. Also, Taurine participates in bile acids and cholesterin exchange with formation of cholyltaurine, which fact, probably, explains its lipidemid properties. Inhibiting effect on rennin-angiotension and callicrein-kynin systems, positive action on products of cyclo-AMP and inhibition of LPO processes are leading mechanisms of realization of cardiovascular effects of preparation Cratal. Thus, Cratal gives an expressed inhibition of rennin activity, resulting in transformation of angiotensin into angiotensin I, a predecessor of angiotensin II, one of most powerful vasoconstrictors. Materials and methods Two groups consisting of 50 male patients having average age 42.7 + 5.3 years were examined. First group included 36 patients with cardiac ischemia and soft arterial hypertension (AH) and the second group included 14 patients with neurocirculatory dystonia (NCD). The first group included 36 patients with cardiac ischemia and soft arterial hypertension (HT), the second one included 14 patients with neurocirculatory dystonia (NCD). All patients with NCD were treated only with Cratal, 1 dose 3 times a day within 10 to 20 days; the rest received the preparation on the background of basic therapy (antagonists of Ca2+, betadrenoblockators, nitrates, APP inhibitors). In the process of examination arterial pressure and heart rate were measured, double product values (DP) before and after therapy were calculated as well as indicators cardiohemodynamics by achocardiographic method and tolerance to a dosed physical load (DPL) using the method of paired ergonomic tests were defined. Levels of plasma electrolytes, uric acid, cholesterin, triglycerides and ferments alanine amine transferase and aspartate amine transferase were analyzed. Preparation efficiency was evaluated in points: very good effect (1 point); good effect (2 points); satisfactory (3 points); poor effect (4 points). The obtained data were processed using methods of variation statistics and package of applied statistical programs. Results and discussion Therapy with preparation Cratal within 10 days resulted in reduction of systole and diastole AT with nest their stabilization, reduction of heart rate and DP, which fact demonstrates more saving operation of myocardium, of reduction of oxygen consumption therein with the same physical activities of patients. The analysis of diastole AT has shown that the value of this indicator reduced in average by 4.1 + 1.1 mm Hg, while individual values varied from +2 to –10 mm Hg. It must be noted that Cratal never increased heart rate as a response to AT reduction. During testing with dosed physical loads it was ascertained that tolerance in 17 patients with cardiac ischemia of 36 remained unchanged, in 10 patients of 36 pedaling time reduced by 30 to 60 s and in 9 patients of 36 pedaling time increased by 60 s. Data of pre-clinical studies of specific pharmacological activity of Cratal have demonstrated that this preparation has a soft cardiotonic effect, high antianginal and coronarolytic activity. The preparation in doses 50 and 100 mg/kg improved blood supply and functional status of experimental ischemia focus, twice reduced lactate separation and redox processes shift in lactate-pyruvate system. The tested preparation increased coronary blood flow rate, increase OH percentage in blood from coronary sinus, thus forming an oxygen reserve in myocardium. When testing rats for physical loads, we have ascertained that hemodynamic, coronarolytic and cardioprotecting activities were added while myocardium functional stability was potentiated. The indicators of cardiodynamics in patients with cardiac ischemia were studied on the background of basic therapy with addition of Cratal, while in patients with neurocirculatory dystonia – on the background of monotherapy using Cratal. The above data show that in the process of therapy some functional index increase is noted. The obtained data are in accordance with pre-clinical experimental study of the preparation conducted in the State scientific center of drugs. Convincing is the fact that the studied preparation caused hypodynamic shifts of hypodynamic system indicators in intact narcotized rabbits and showed positive inotropic action in dogs within the period of acute myocardium infarction. In doses 50, 100 and 200 mg/kg Cratal gave a protective effect on model of pituitrin-neopinephrine cardiomypathy in rats, preventing creatures death and change of myocardium contractility indicators. On the background of modeling of aorta coarctation at the compensation stage Cratal prevented the development of tachycardia and increased contractility indicators. In the process of therapy with preparation Cratal in all patients general feeling significantly improved. In patients with cardiac ischemia the number of stenocardia attacks and of the use of nitroglycerin tablets reliably dropped. An expressed sedative effect is a distinctive feature of this preparation. So, in patients with NCD a confident reduction (р < 0,05) of both number and gravity of sympatho-adrenal crisis. With clinical approbation of preparation Cratal no side effects were noted, the preparation did not affect blood count indicators (total and biochemical blood counts). Preparation efficiency was evaluated as good (2 points). With the use of preparation Cratal the efficiency of basic therapy is potentiated. Our studies have shown that it may be used in combination with nitrates of long-time action, with vasodilators, cardiac glycosides and diuretics. Thus, Cratal is a promising drug, which may be used in a complex therapy of diseases cardiovascular system of different origin. The implementation of preparation Cratal in a wide medical practice will facilitate widening of adequate therapy potentialities.